# EDGAR Filing Document

**Accession Number:** 0000926617
**File Stem:** 0000926617-23-000006
**Filing Date:** 2023-1
**Character Count:** 6804
**Document Hash:** bfdd23b786ecf944968513e381925f1b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000926617-23-000006.hdr.sgml**: 20230110

**ACCESSION NUMBER**: 0000926617-23-000006

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 31

**CONFORMED PERIOD OF REPORT**: 20230110

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230110

**DATE AS OF CHANGE**: 20230110

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Aspira Women's Health Inc.
- **CENTRAL INDEX KEY:** 0000926617
- **STANDARD INDUSTRIAL CLASSIFICATION:** IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
- **IRS NUMBER:** 330595156
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-34810
- **FILM NUMBER:** 23519730

**BUSINESS ADDRESS:**
- **STREET 1:** 12117 BEE CAVES ROAD BUILDING THREE
- **STREET 2:** SUITE 100
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78738
- **BUSINESS PHONE:** 512-519-0400

**MAIL ADDRESS:**
- **STREET 1:** 12117 BEE CAVES ROAD BUILDING THREE
- **STREET 2:** SUITE 100
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78738

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** VERMILLION, INC.
- **DATE OF NAME CHANGE:** 20070824

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CIPHERGEN BIOSYSTEMS INC
- **DATE OF NAME CHANGE:** 20000316

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ABIOTIC SYSTEMS
- **DATE OF NAME CHANGE:** 19950407

?xml version="1.0" encoding="utf-8"? awh-20230110x8k

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of**

**The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): January 10, 2023**

**Aspira Women's Health Inc.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-34810** | **33-0595156** |
| (State or other jurisdiction | (Commission | (IRS Employer |
| of incorporation) | File Number) | Identification No.) |

---

---

| | |
|:---|:---|
| **12117 Bee Caves Road, Building Three, Suite 100, Austin, Texas** | **78738** |
| (Address of principal executive offices) | (Zip Code) |

---

**Registrant's telephone number, including area code: (512) 519-0400**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

  <br> <u>☐</u> <u>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </u>

    <br> <u>☐</u> <u>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </u>

  <br> <u>☐</u> <u>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </u>

  <br> <u>☐</u> <u>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </u>

------

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| <u>Title of each class</u> | <u>Trading Symbol(s)</u> | <u>Name of each exchange on which registered</u> |
| Common Stock, par value $0.001 per share | AWH | The Nasdaq Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 **‎** 

------

**Item 7.01 Regulation FD Disclosure.**

On January 10, 2023, Aspira Women's Health Inc. will be presenting to investors. A copy of the investor presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K filing.

**Item 9.01 Financial Statements and Exhibits.** 

(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Exhibits

---

| | |
|:---|:---|
| <u>Exhibit No.</u> | <u>Description</u> |
| [<u>99.1</u>](awh-20230110xex99_1.htm) | [<u>Investor Slides to be Presented by Aspira Women's Health Inc. on January 10, 2023</u>](awh-20230110xex99_1.htm) |

---

 **‎** 

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  |  | ASPIRA WOMEN'S HEALTH INC. |
| Date: January 10, 2023 | By: | /s/ Marlene McLennan |
|  |  | Marlene McLennan |
|  |  | Interim Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![Graphical user interface, text, application, email Description automatically generated](awh-20230110xex99_1g001.jpg)

------

![Text, letter Description automatically generated](awh-20230110xex99_1g002.jpg)

------

![Graphical user interface, text, application Description automatically generated](awh-20230110xex99_1g003.jpg)

------

![Website Description automatically generated with medium confidence](awh-20230110xex99_1g004.jpg)

------

![Text, email Description automatically generated](awh-20230110xex99_1g005.jpg)

------

![Text Description automatically generated](awh-20230110xex99_1g006.jpg)

------

![Graphical user interface, website Description automatically generated](awh-20230110xex99_1g007.jpg)

------

![Graphical user interface, website Description automatically generated](awh-20230110xex99_1g008.jpg)

------

![Timeline Description automatically generated](awh-20230110xex99_1g009.jpg)

------

![Chart Description automatically generated](awh-20230110xex99_1g010.jpg)

------

![Graphical user interface, text, application, email Description automatically generated](awh-20230110xex99_1g011.jpg)

------

![Diagram Description automatically generated](awh-20230110xex99_1g012.jpg)

------

![Chart, line chart Description automatically generated](awh-20230110xex99_1g013.jpg)

------

![Graphical user interface, text, application, email, website Description automatically generated](awh-20230110xex99_1g014.jpg)

------

![Graphical user interface, text, application Description automatically generated](awh-20230110xex99_1g015.jpg)

------

![Graphical user interface, application Description automatically generated](awh-20230110xex99_1g016.jpg)

------

![Graphical user interface, text, application, email Description automatically generated](awh-20230110xex99_1g017.jpg)

------

![Website Description automatically generated with medium confidence](awh-20230110xex99_1g018.jpg)

------